Discovery of potent dual GPBAR1/CysLT1R modulator for the treatment of metabolic fatty liver disease

Nonalcoholic steatohepatitis (NASH) is a highly prevalent human disorder for which no approved treatment is currently available. Several mediators are involved in the development of liver inflammation and fibrosis in NAFLD/NASH patients. Among the several targets, the cysteinyl leukotriene receptor 1 (CysLT1R) and the bile acid receptor GPBAR1, have been shown to be involved in disease development in several animal models of NAFLD/NASH. This study characterized the liver transcriptomic profile of mice fed a high fat diet and treated with a potent dual GPBAR1/CysLT1R modulator.